Concurrent use with docetaxel, doxorubicin or irinotecan ... with a high incidence of grade 3 hand–foot syndrome/skin reaction (45%). Sorafenib-plus-paclitaxel demonstrated a statistically ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback